Sufentanil
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Sufentanil
- Sufentanil: From Anesthesia and Severe Pain Management to Nephrogenic Syndrome of Inappropriate Antidiuresis
Sufentanil: From Anesthesia and Severe Pain Management to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Sufentanil is a potent synthetic opioid analgesic, established in clinical practice for general anesthesia and severe pain management (e.g., epidural/intrathecal analgesia). The TxGNN model predicts it may be effective for Nephrogenic Syndrome of Inappropriate Antidiuresis, but this prediction is currently supported by 0 clinical trials and 0 publications, and the accompanying mechanistic analysis found no plausible biological rationale connecting opioid pharmacology to this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anesthesia / severe pain management (based on established pharmacology; no EU marketing authorization is on record in this dataset) |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis |
| TxGNN Prediction Score | 97.41% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for sufentanil is not available in this Evidence Pack. Sufentanil is a fentanyl-class synthetic opioid that acts as a potent μ-opioid receptor agonist, a mechanism well established for producing analgesia and anesthesia but with no documented physiological link to renal water handling or antidiuretic hormone signaling.
The repurposing rationale provided alongside this prediction explicitly states that there is no known mechanistic connection between μ-opioid receptor agonism and the syndrome of inappropriate antidiuresis / sodium-water metabolism pathway. This candidate arises purely from TxGNN’s knowledge-graph embedding similarity, without any supporting biological or clinical pathway.
Consequently, this prediction should be treated as a hypothesis-generating signal only, not as a candidate with plausible pharmacological grounding. None of the other nine ranked predictions in this Evidence Pack (common cold, gastroduodenitis, peptic ulcer disease, exercise-induced malignant hyperthermia, headache disorder, trigeminal autonomic cephalalgia, familial periodic paralysis, nephrogenic diabetes insipidus, obsolete rare pulmonary disease) fare better — several rationales note that opioid pharmacology is directionally unfavorable for the predicted disease (e.g., opioids worsen GI motility disorders, and opioids are explicitly discouraged as first-line therapy for headache disorders due to medication-overuse-headache risk).
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the SmPC for safety information.
Note: A blocking data gap has been identified — TFDA/EU label warnings and contraindications for sufentanil have not yet been retrieved, which currently prevents this candidate from entering the S1 safety pre-screening stage.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Nephrogenic Syndrome of Inappropriate Antidiuresis) has no clinical trial or literature support and no plausible mechanistic link — the rationale itself characterizes it as a pure embedding artifact. Combined with a blocking gap in safety labeling data, this candidate does not meet the threshold to proceed past initial screening.
To proceed, the following is needed:
- Retrieve TFDA/EU SmPC warnings, contraindications, and drug-drug interaction data (currently blocking S1 safety review)
- Retrieve detailed mechanism of action (MOA) data from DrugBank to support or refute mechanistic plausibility
- Re-evaluate lower-ranked candidates with at least partial evidence (e.g., headache disorder [L4], nephrogenic diabetes insipidus [L4]) as these have marginally more literature signal than the top-ranked prediction, despite unfavorable mechanistic direction
- If pursuing further, obtain confirmed original indication and EU marketing status, as this drug currently shows zero EU authorizations in the dataset
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.